Introduction {#S0001}
============

The incidence of melanoma is increasing steadily both in Poland and worldwide. Melanoma presents the highest death rate among young people between 20 and 29 years of age. The mortality to incidence ratio in Poland is much higher than in Western Europe \[[@CIT0001]\]. More than 2500 skin melanomas were diagnosed in Poland in 2009. Over 1000 patients will die each year due to metastatic disease \[[@CIT0002]\]. Thus, there is a critical need to improve the understanding, prevention, and treatment of this malignancy.

Until 2010 three drugs were approved for the treatment of metastatic melanoma -- dacarbazine (DTIC) in Europe and USA, fotemustine in Europe and interleukin-2 (IL-2) in USA. However, none of these drugs showed beneficial effects on survival of patients in phase III trials. Although objective responses after standard treatment are being observed, as well as a few long-term remissions after IL-2 (less frequently after chemotherapy), no predictive factors for these treatment strategies are known. Multidrug chemotherapy consisting of DTIC (BOLD, CVD, Dartmouth) results in a higher response rate, although is not beneficial in terms of survival over DTIC alone. Also commonly used temozolomide or paclitaxel with or without carboplatin did not result in overall survival (OS) prolongation \[[@CIT0001]\]. In addition, various strategies of combining chemotherapy with biotherapy did not bring significant benefits to patients \[[@CIT0003]\].

Recent approval of ipilimumab and vemurafenib in Europe and USA changed the standard of care of metastatic melanoma patients. Moreover, positive results of phase III trials evaluating dabrafenib and trametinib may lead to approval of these drugs in the near future. A number of new small molecules or immunotherapy strategies are currently in various stages of clinical development in metastatic melanoma.

Lack of effective treatment in patients with high-risk resected melanoma led to a number of clinical trials. Several randomised phase III studies evaluating interferon (IFN)-α-2a and IFN-α-2b in low, medium and high doses have been carried out. Only in two of them was a statistically significant improvement of OS observed. High-dose IFN-α-2b (Intron^®^) has been approved by the U.S. FDA (Food and Drug Administration) based on the results of the ECOG 1684 trial. At a median follow-up of 6.9 years the study demonstrated a statistically significant improvement in survival for patients treated with IFN-α-2b compared to the control group. However, at 12.6 years of follow-up, OS was not significantly different between the two study groups. Intron is indicated in patients after resection of high-risk melanoma (stage IIB and stage III). Recently (March 2011) pegylated-IFN-α-2b (Sylatron^®^) has been approved for the treatment of patients with melanoma with microscopic or gross nodal involvement after definitive surgical resection including complete lymphadenectomy. The approval was based on the results of the EORTC 18991 trial. The study demonstrated a lack of survival benefit with the improvement in recurrence-free survival (RFS) in unselected patients treated with Sylatron compared to the placebo control \[[@CIT0004]\]. Despite approval of IFN in the adjuvant treatment of melanoma its use in the clinic is limited due to the high toxicity and questionable effectiveness. Currently we are awaiting the results of two melanoma adjuvant phase III studies evaluating ipilimumab and MAGE-A3 ASCI vaccine \[[@CIT0005], [@CIT0006]\].

Kinase inhibitors {#S0002}
=================

In recent years genetic and molecular studies and a number of somatic mutations playing a key role in melanoma pathogenesis have been identified. Moreover, understanding the underlying mechanisms leading to melanoma cell progression resulted in the development of targeted therapies in the treatment of melanoma patients. The best defined mutations are in oncogenes, *NRAS*, *BRAF*, *c-KIT*, *GNAQ*, *GNA11* and suppressor genes such as *PTEN* or *P53*. Very recently driver mutations in PPP6C, RAC1, SNX31, TACC1, STK19, and ARID genes were described in UV (sun) dependent melanoma \[[@CIT0007]\].

BRAF inhibitors {#S20003}
---------------

BRAF is a member of the Raf family of serine threonine kinases (ARAF, BRAF, CRAF) which are part of the Ras/ Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway. Activation of the MAPK pathway results in increased transcription of genes required for cell cycle entry. *BRAF* mutations are identified in 40-60% of melanomas. The most common is *V600E*, which occurs in 80% of *BRAF* mutant melanoma cells. Less frequent are *V600K* and *V600* D/R, identified in 16% and 3%, respectively \[[@CIT0009]\]. *BRAF* mutation usually occurs in younger patients (\< 55 years) with the localization of primary melanoma on the trunk. *BRAF* mutation is not associated with constant sun exposure but is more often related to frequent solar burns during childhood \[[@CIT0010]--[@CIT0012]\]. *BRAF* mutation is also a prognostic factor linked with a poorer survival (8.5 vs. 5.7 months in *BRAF* wild-type and *BRAF* mutant melanoma, respectively) \[[@CIT0009]\].

Sorafenib, a multikinase inhibitor, was the first *RAF* inhibitor tested in clinical trials. Sorafenib inhibits not only mutated *BRAF* but also *BRAF* wild type and *C-KIT* mutated melanoma as well as PDGFR (platelet-derived growth factor receptor) and VEGFR (vascular endothelial growth factor receptor) -2 and -3 \[[@CIT0013]\]. However, sorafenib in combination with carboplatin and paclitaxel did not show an advantage over chemotherapy in a phase III study.
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The only BRAF inhibitor approved so far by the U.S. FDA and EMA (European Medicine Agency) in the treatment of metastatic melanoma is vemurafenib. This selective BRAF inhibitor has been tested in a phase 2 trial (BRIM2) in patients with metastatic melanoma with confirmed *BRAF V600E* mutation after progression of earlier systemic treatment. The observed overall response rate was 53% \[6% with a complete response (CR) and 47% with a partial response (PR)\]. The median duration of response was 6.7 months. Primary progression was observed only in 14% of patients. Some patients responded after receiving vemurafenib for more than 6 months. The median OS was 15.9 months \[[@CIT0014]\]. Vemurafenib was also evaluated in a phase 3 trial (BRIM3) which led to its approval by the FDA in August 2011 and by the EMA in February 2012. In the BRIM3 trial vemurafenib was studied as the first line treatment in metastatic melanoma patients with *BRAF V600E* mutation. 675 patients were randomly assigned to the vemurafenib treatment arm (960 mg twice daily) or DTIC control arm (1000 mg/m^2^ every 3 weeks). At the time of study analysis the objective response rate was higher in patients receiving vemurafenib (48% vs. 5.5%). The median progression-free survival (PFS) was longer in patients treated with the study drug \[5.3 vs. 1.6 months; hazard ratio (HR) 0.26; 95% confidence interval (CI) 0.20--0.38; *p* \< 0.001\]. HR for death in the vemurafenib group was 0.37 (95% CI: 0.26--0.55; *p* \< 0.001). At 6 months, OS was 84% for patients receiving vemurafenib and 64% for those treated with DTIC. Clinical benefit in patients receiving vemurafenib was independent of age, gender, ECOG (Eastern Cooperative Oncology Group) performance status, stage or level of LDH (lactate dehydrogenase). Generally treatment with vemurafenib was well tolerated. The most common adverse events (AEs) were grade 1 or 2 and included arthralgia, rash, photosensitivity, nausea, fatigue and alopecia. Cutaneous squamous-cell carcinoma or keratoacanthoma was diagnosed in 26% of patients participating in BRIM2 and 18% in the BRIM3 study \[[@CIT0014], [@CIT0015]\]. Updated OS results of the BRIM3 study have been presented at the 2012 ASCO (American Society of Clinical Oncology) annual meeting. The overall response rate in patients treated with vemurafenib was 57% (5.6% -- CR, 51.3% -- PR) compared with 8.6% (1.2% -- CR, 7.4% -- PR) observed in patients receiving DTIC. Median PFS at this time point of the study was 6.9 months in patients treated with the study drug and 1.6 months in patients receiving chemotherapy (HR 0.38; 95% CI: 0.32--0.46; *p* \< 0.001). The median OS was also statistically longer in patients treated with vemurafenib (13.6 vs. 9.7 months; HR 0.70; 95% CI: 0.57--0.87; *p* \< 0.001). The earlier analysis of the BRIM3 study demonstrated 63% reduction of risk of death, while the updated results showed a 30% risk reduction. The study also demonstrated lower OS benefit in stage IIIc and IV-M1a/M1b than M1c in patients treated with vemurafenib compared to DTIC. These differences might be due to the higher number of patients treated with ipilimumab in the DTIC group after the study completion (26% vs. 18%). In patients treated with vemurafenib, adverse cutaneous skin carcinoma, keratoacanthoma and skin papilloma were noted respectively in 19%, 11% and 28% of patients \[[@CIT0016]\].

Recently, results of an open-label, multicenter safety study of vemurafenib in patients with metastatic melanoma were presented. Of 1964 screened patients, 914 were enrolled in the study and 834 were evaluable for toxicity analysis. 30% of patients did not receive any prior systemic treatment due to the metastatic melanoma. AEs were observed in 66% of patients and were mainly related to vemurafenib treatment. The most frequently observed AEs of any grade were arthralgia (31%), rash (29%), fatigue (22%), photosensitivity (21%) and nausea (15%). 33% and 1.9% of patients developed grade 3 and 4 AEs, respectively. The most frequently observed were rash (3.6%), arthralgia (3.1%) and cutaneous cell carcinoma/keratoacanthoma (4.3%). In 6% of patients treatment was discontinued due to AEs (mainly arthritis and abdominal pain). At the time of study analysis 302 patients were evaluable for tumour assessment at week 8 of treatment; 61% developed objective responses, and 29% stable disease (SD) \[[@CIT0017]\].

Another active BRAF kinase inhibitor is dabrafenib (GSK2118436), evaluated in a randomized, open-label, multicenter phase 3 study (BREAK-3) in patients with *BRAF V600E* mutated metastatic melanoma. In the study arm previously untreated patients received oral dabrafenib at a dose of 150 mg twice a day, while in the control arm they received DTIC at a dose of 1000 mg/m^2^ every three weeks. ECOG performance status greater than 1 was noted in 31% of patients and 66% had stage M1c melanoma. The objective response rate was higher in patients treated with dabrafenib -- 53% vs. 19%. Patients in the study arm had longer median PFS -- 5.1 vs. 2.7 months (HR 0.30; 95% CI: 0.18--0.53; *p* \< 0.0001). The OS data were immature for analysis at this point of the study. The most common AEs noted in patients treated with dabrafenib were hyperkeratosis (37%), headache (32%), pyrexia (28%), arthralgia (27%) and skin papillomas (24%). Grade 3 and 4 toxicity included pyrexia (6%), squamous cell carcinoma (6%) and new primary melanoma (2%) \[[@CIT0018]\].

Vemurafenib compared to dabrafenib more frequently caused photosensitivity, while dabrafenib caused pyrexia refractory to antipyretics.

A number of clinical trials have shown low efficacy of anti-cancer agents in melanoma patients with brain metastases. However, small molecules have demonstrated some efficacy in patients with solid tumours with concomitant brain metastases.

Dabrafenib demonstrated high clinical efficacy in patients with *BRAF V600E/K* mutation with intracranial lesions. In a phase 2 study (BREAK-MB) stage IV melanoma patients with ≥ 1 intracranial metastases were enrolled. 127 patients were recruited to one of the two study arms, but only 41 patients reached 8-week disease assessment at the time of interim analysis. Patients in cohort A did not receive any prior brain metastasis treatment before entering the trial. Patients in group B before enrolment developed intracranial progression following prior brain therapy. A 53% unconfirmed overall intracranial response rate (OIRR) was reached in patients with the BRAF V600E mutant in both study cohorts. The unconfirmed OIRR was 20% and 50%, respectively, in arms A and B. These preliminary results confirm efficacy of dabrafenib in melanoma patients with intra- and extracranial metastases with acceptable toxicity \[[@CIT0019]\].

MEK inhibitors {#S20004}
--------------

The observation that nearly all melanomas demonstrate constitutive MAPK activity led to the development of small-molecule MEK inhibitors, such as PD0325901, selumetinib (AZD6244) and CI-1040, tested in an unselected group of melanoma patients. Initial studies evaluating these MEK inhibitors were disappointing, limiting their further evaluation mainly due to high toxicity \[[@CIT0020]\]. Interest in the clinical development of MEK inhibitors was renewed by the development of a reversible, highly selective allosteric inhibitor of MEK 1/2 -- GSK1120212 (trametinib), tested in a phase 3 (METRIC) study. In the study arm *BRAF V600/K* mutant advanced or metastatic melanoma patients were treated with trametinib, while in the control arm patients were treated with chemotherapy (paclitaxel/DTIC). Patients on chemotherapy were allowed to cross over to the trametinib arm after disease progression. The overall response rate was greater in patients treated with trametinib -- 24% vs. 7%. In the group receiving trametinib the median PFS was longer than in the control arm -- 4.8 vs. 1.4 months (HR 0.44; 95% CI: 0.31--0.64; *p* \< 0.0001). The 6-month OS in the trametinib group was 81% compared with 67% in the chemotherapy group (HR 0.53; 95% CI: 0.30--0.94; *p* \< 0.01). The most frequently observed adverse events in patients treated with trametinib included skin rash, diarrhoea, oedema, hypertension and fatigue. Characteristic AEs associated with MEK inhibitor treatment included chorioretinopathy (\< 1%) and decreased ejection fraction (7%) \[[@CIT0021]\].

Overcoming resistance to BRAF inhibitors {#S20005}
----------------------------------------

BRAF inhibitors induce spectacular tumour shrinkage in patients with *BRAF* mutant melanoma, although these responses are short-lived due to the secondary resistance to the drug observed in nearly all treated patients (median PFS around 7 months) \[[@CIT0020]\]. A number of potential BRAF inhibitor resistance mechanisms have been reported, which mostly depend on a common set of signalling pathways. Basic studies have already demonstrated that reactivation of MAPK signalling is usually related to vemurafenib resistance. Combination of MEK and BRAF inhibitors was effective at overcoming the resistance mediated by *MEK1* mutations, COT overexpression, BRAF truncation and acquired *Ras* mutations \[[@CIT0022]--[@CIT0025]\].

A combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) was tested in a phase I/II study in 77 *BRAF V600* mutant metastatic melanoma patients. The observed overall response rate was 56% with 4 CR, 39 PR, 29 SD and 3 PD. Overall PFS was 7.4 months. Pyrexia (6.5%), fatigue (6.5%) and dehydration (6.5%) were the most commonly noted serious AEs. Dabrafenib combined with trametinib was associated with a lower incidence of MEK inhibitor related rash and BRAF inhibitor induced hyperproliferative skin lesions when compared to the single agent treatment. Skin toxicity over grade 2 occurred in nearly 2% of patients. Cutaneous squamous cell carcinoma and keratoacanthoma were observed in 2% of patients \[[@CIT0026]\].

C-KIT inhibitors {#S20006}
----------------

Activating mutations in *KIT* have been discovered in acral melanomas and melanomas arising from mucosal or chronically sun-damaged sites. Previously *KIT* was believed to function as a tumour suppressor, but further research suggested that in certain contexts, *KIT* functions as an oncogene. KIT encodes type III transmembrane receptor tyrosine kinases. Three subsequent phase II studies evaluating imatinib in metastatic melanoma patients with *KIT* mutation or amplification have been conducted. Imatinib is a tyrosine kinase receptor inhibitor, which selectively inhibits the tyrosine kinases of the bcr-abl, c-KIT, and PDGFR (platelet-derived growth factor receptors). Findings in these studies are consistent, with the observed objective response rate around 25%. Interestingly, responses to imatinib treatment were observed only in patients with the *KIT* mutation located in exons 11 and 13 \[[@CIT0008]\].

Recently results of a phase II study testing dasatinib in patients with advanced or metastatic mucosal, acral and solar melanomas have been presented. Dasatinib\'s mechanism of action is similar to imatinib. Out of 57 enrolled patients, *KIT* status assessment was performed in 42 cases with only 3 presenting *KIT* mutation. An objective response was observed in 7% of patients and SD was noted in 25%. The second stage of this trial will enrol only patients with *KIT* mutation \[[@CIT0027]\].

The only randomized phase III trial conducted in *KIT* mutant melanoma was initiated in 2010. The study evaluated efficacy of nilotinib compared with DTIC \[[@CIT0028]\]. However, challenging accrual due to uncommon *KIT* mutation in melanoma forced the sponsor to modify this study to a single arm phase II trial assessing nilotinib alone. These results of drugs for melanomas harbouring the *KIT* mutation need further evaluation. Currently additional agents targeting KIT and evaluating KIT inhibitors in combinations with other drugs are ongoing \[[@CIT0008]\].

Immunotherapy {#S0007}
=============

Anti-CTLA-4 {#S20008}
-----------

Another new drug approved for the treatment of metastatic melanoma is ipilimumab (Yervoy^®^). Ipilimumab is a fully human monoclonal antibody (mAb) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). CTLA-4 is an immune checkpoint molecule that is up-regulated on activated T-cells. It suppresses further activation of specific CD4+ and CD8+ T-cells by interaction with dendritic cells (DCs) or directly as a result of a contact between suppressor and effector T lymphocytes. The anti-CTLA4 mAb by blocking the interaction of CTLA-4 with CD80/86 switches off the mechanism of immune suppression and enables continuous, unrestrained stimulation of T-cells by DCs \[[@CIT0001]\]. Two IgG mAb directed against CTLA-4 -- ipilimumab and tremelimumab -- have been tested in number of clinical trials in patients with melanoma. Ipilimumab was first approved in the U.S. (2010) and subsequently in Europe (2011) for the second line treatment after failure of chemotherapy. Ipilimumab is also accepted for treatment of previously untreated patients with metastatic melanoma (only in the U.S.) The approval was based on the results of a randomized phase III trial, which included 676 HLA-A\*0201-positive patients with unresectable stage III or IV melanoma. Patients enrolled were previously treated with IL-2 or chemotherapy and were then randomly assigned to ipilimumab plus peptide (gp100) vaccine (403 patients), ipilimumab alone (137), or gp100 alone (136) study groups. Ipilimumab, at a dose of 3 mg/kg, was administered with or without gp100 every 3 weeks for up to four treatments. Treatment with ipilimumab was associated with a 32% and 34% reduction of death-related risk when administered with gp100 or in monotherapy. Patients receiving ipilimumab alone or in combination with the peptide vaccine had a nearly identical median OS of 10 and 10.1 months, compared with 6.4 months in patients receiving gp100 alone (*p* \< 0.001). Two-year OS was observed in 23% of patients treated with ipilimumab, and in 14% in the control arm \[[@CIT0029]\]. Ipilimumab was also tested in a phase III trial in previously untreated metastatic melanoma patients. In the study arm patients received 10 mg/kg ipilimumab with DTIC while in the control arm they received DTIC alone. OS was longer in patients treated with the study drug (11.2 vs. 9.1 months; HR = 0.72; *p* = 0.0009). Two-year OS was observed in 28.5% of patients receiving ipilimumab and 17.9% in the control arm. The three-year OS rate was 20.8% in patients of the study arm and 12.2% in the DTIC group \[[@CIT0030]\]. New OS data from two phase II studies, CA184-008 and CA184-22, in patients treated with 10 mg/kg ipilimumab demonstrated a 2-year OS rate of 30% and 24% and a 3-year OS rate of 25% and 24% respectively \[[@CIT0031], [@CIT0032]\].

Treatment with ipilimumab causes so-called immune-related adverse events (irAE), which occur in 80% of patients. Grade 3-5 irAE were observed in 7--13% of patients treated with 3 mg/kg ipilimumab, while a higher 10 mg/kg dose caused grade 3--4 toxicity in 22--39% of patients \[[@CIT0033]--[@CIT0036]\]. The most frequently observed irAE were diarrhoea, colitis, endocrinopathies, dermatitis and hepatitis. These irAE specific for anti-CTLA-4 are quite easy to manage using glucocorticosteroids \[[@CIT0037]\]. At the 7^th^ International Melanoma Congress in 2010 it was reported that when the ipilimumab treatment was preceded by administration of GM-CSF-gene modified autologous cell melanoma vaccine, grade 3 and 4 irAE were not observed. These results indicate that future effective ipilimumab therapy may require concomitant induction of specific anti-melanoma T cell clones \[[@CIT0038]\].

The objective response rate observed in phase II and III studies in patients treated with ipilimumab was 7--15% \[[@CIT0039]\]. Responses were correlated with irAE \[[@CIT0040]\]. 36% of patients with grade 3 and 4 toxicity developed objective responses, while in patients without irAE responses occurred in 5--11% \[[@CIT0041]\]. Median time to response was 12 weeks with a median duration of 11.5 months \[[@CIT0042]\]. 68% of patients responded after 12 weeks from the beginning of the treatment with ipilimumab. Retrospective analysis of two phase II studies (CA 184-022 and CA 184-008) demonstrated that 39% of patients with disease progression according to modified WHO criteria benefited from the ipilimumab treatment and their tumour assessment might be evaluated as PR or SD using immune-related response criteria (irRC) \[[@CIT0043]\].

During the 2012 ASCO meeting results of the ipilimumab U.S. expanded access program (EAP) in patients with unresectable stage III or IV melanoma were presented. The study also enrolled patients with brain metastases (27%), ocular melanoma (5%) and mucosal melanoma (4%). 906 patients were treated with ipilimumab at a dose of 10 mg/kg every 3 weeks (4 doses -- induction phase) followed by 10 mg/kg every 12 weeks (maintenance phase) until progression or unacceptable/unmanageable toxicity of the treatment. Durable OS over 3 years was observed in 17% of patients. IrAE were noted in 27% of patients, while 11% of patients discontinued treatment due to drug toxicity \[[@CIT0044]\]. Currently a randomized, double-blind, phase III trial comparing two doses of ipilimumab, 3 mg/kg vs. 10 mg/kg, in metastatic melanoma patients has finished enrolment \[[@CIT0045]\].

Treatment with vemurafenib following ipilimumab therapy seems to be associated with hypersensitivity skin reactions in patients with metastatic melanoma. Rash associated with vemurafenib was observed in 13 out of 16 treated patients (81%). Four patients developed grade 3 maculopapular rash which occurred 8 days following initiation of the vemurafenib treatment. Biopsies demonstrated spongiotic and perivascular dermatitis with eosinophils consistent with a drug hypersensitivity reaction. Progression towards life-threatening reactions such as anaphylaxis or Stevens-Johnson syndrome which would require discontinuation of vemurafenib treatment was not observed. The incidence of grade 3 rash was higher than observed in patients treated with vemurafenib in the phase III BRIM3 trial (25% vs. 8%; *p* = 0.02) \[[@CIT0046]\]. Currently a phase I/II trial evaluating ipilimumab in combination with vemurafenib is active with the first enrolled metastatic melanoma (*BRAF V600* mutant) patients in the fourth quarter of 2011 \[[@CIT0047]\].

Ipilimumab has also shown some activity in patients with metastatic melanoma and brain metastases, particularly when metastases were small and asymptomatic. In a recently published phase II study a 24% and 10% intracranial response rate was observed, respectively in patients neurologically asymptomatic without concomitant corticosteroid treatment and with neurological symptoms on a stable dose of corticosteroids \[[@CIT0048]\].

Ipilimumab was also evaluated in combination with fotemustine (NIBIT-M1 trial) in 86 patients with asymptomatic brain metastases (7 patients had undergone earlier whole brain radiotherapy or radiosurgery). Four doses of 10 mg/kg ipilimumab were administered every 3 weeks with a weekly 100 mg/m^2^ dose of fotemustine for 3 weeks, followed by ipilimumab every 12 weeks (from week 24) combined with fotemustine every 3 weeks (from week 9). The immune-related (ir) disease control rate (irDCR = CR + PR + SD using the ir response criteria) was 50% and the immune-related overall response rate (irORR = CR + PR) was 40%. Median irPFS was 4.6 months and 1-year OS was 52%. Median OS was not reached at the time of study analysis. 60% of patients developed grade 3 or 4 toxicity (haematological toxicity -- 50%, elevated ALT/AST -- 5%, gastrointestinal adverse events -- 5%) \[[@CIT0049]\].

Tremelimumab is another mAb targeting CTLA-4. It was administered in phase II at the dose of 15 mg/kg every 3 months to previously treated patients. In 8.3% of 256 metastatic melanoma patients enrolled, objective clinical responses were observed, while the median OS was 10.2 months \[[@CIT0050]\]. In the phase III trial 643 patients were treated with tremelimumab in monotherapy or with DTIC/temozolomide (TMZ) in the first line setting. Analysis of preliminary results failed to show the advantage of tremelimumab over the standard therapy (OS 11.8 vs. 10.7) and the trial was terminated \[[@CIT0051]\]. Treatment effectiveness of tremelimumab in combination with high doses of interferon-α-2b was evaluated in a small phase II trial which enrolled only 16 patients with inoperable stage III and IV melanoma. A clinical response was observed in 19% of patients. The most frequent grade 3 and 4 adverse events included neutropenia in 3 patients (19%), elevated liver enzymes in 2 (13%), fatigue in 6 (38%) and anxiety in 2 (13%) \[[@CIT0052]\].

Anti-PD-1 {#S20009}
---------

Another human mAb modulating the immune system is BMS-936558 (MDX-1106) directed against the programmed death-1 receptor (PD-1R), the ligand of which (PD-1L) can be directly expressed on melanoma cells. PD-1R is a part of the B7:CD28 family of co-stimulatory molecules that regulate T-cell activation and tolerance, and thus anti-PD-1R can play a role in breaking tolerance \[[@CIT0053]\]. BMS-936558 was tested in 95 metastatic melanoma patients undergoing earlier systemic therapy. The study drug was administered intravenously every 2 weeks until PD or CR, for a maximum of 12 cycles. The doses varied depending on the study cohort (0.1--10 mg/kg). Grade 3 and 4 toxicity was observed in 19% of patients, mainly including gastrointestinal (4%), endocrine (2%) and hepatobiliary disorders (1%). The objective response rate was 20--41% depending on the study cohort. Of the 20 patients who responded to the treatment, 12 developed a response lasting over 1 year. BMS-936558 is currently being evaluated in further clinical trials \[[@CIT0054]\]. BMS-936558 was also tested with the combination of a multipeptide vaccine in a phase I study in 30 previously treated metastatic melanoma patients. The vaccine consisted of MART-1/gp100/NY-ESO-1 peptides with adjuvant Montanide ISA 51. In all study cohorts patients responded to the treatment (1/3/10 mg/kg -- 2PR/5PR/2PR and 1 SD). Immunological tests demonstrated decreased PD-1 receptors on CD4+ and CD8+ lymphocytes, decreased CTLA4 receptors on CD8+ and increased CTLA4 receptors on CD4+ cells \[[@CIT0055]\].

Other agents modulating the immune system {#S20010}
-----------------------------------------

The mAb BMS-663513 targeting co-stimulating molecule CD137 (4-1BB) acts according to a different mechanism. Binding of the ligand or anti-CD137 antibody with 4-1BB receptor on the surface of T lymphocytes provides a co-stimulating signal enhancing the cell\'s activation and triggering its proliferation. The phase I trial enrolling 54 patients with solid tumours has shown an acceptable toxicity level and a certain clinical activity of BMS-663513 \[[@CIT0056]\]. We look forward to the results of a large randomized phase II study which has just been completed \[[@CIT0057]\]. CP-870.893 is a human agonistic mAb to co-stimulating molecule CD40 that is up-regulated on the surface of the antigen-presenting cells (APCs). A phase I trial has shown PR in 4 (27%) out of 15 patients with advanced melanoma and 1 CR lasting 18 months after single administration of the drug \[[@CIT0058]\]. Currently, the trial evaluating the efficacy of CP-870,893 in combination with carboplatin and paclitaxel has been completed and the results probably will be disclosed soon \[[@CIT0059]\].

Cancer vaccines {#S20011}
---------------

Whole tumour cell vaccines and stimulating adjuvants were among the first and fundamental specific tumour immunotherapy strategies. In 1990 Berd and colleagues tested autologous melanoma vaccine with BCG (Bacillus Calmette-Guerin) in patients with metastatic melanoma. The median OS observed in these patients was 10 months. The next generation of cancer vaccines consisted of established cell lines (allogeneic vaccines) which present antigens specific for a given tumour type. The immunogenicity of allogeneic vaccines is improved by the response to alloantigens expressed on the vaccine cells. Allogeneic vaccines have superseded autologous vaccines due to the difficulties in obtaining a sufficient number of cells for repeated vaccinations \[[@CIT0003]\]. An example of allogeneic polyvalent cancer vaccine is Cancervax, consisting of three established melanoma cell lines and BCG as an adjuvant. After encouraging results of a phase II study, Cancervax did not improve survival in a phase III trial in metastatic melanoma patients \[[@CIT0060]\]. Encouraging results of a phase II study evaluating Melacine led to a phase III study in patients with metastatic melanoma. Melacine is a melanoma tumour cell lysate vaccine composed of two allogeneic melanoma cell lines (MSM-M-1 and MSM-M-2) combined with Detox^®^ adjuvant \[[@CIT0061]\]. Melacine did not improve survival in vaccinated patients compared to the control group. However, retrospective analysis showed that patients receiving Melacine and expressing at least two of five human leukocyte antigens (HLA) present on the vaccine cells developed longer RFS and OS (*p* = 0.0002 and *p* = 0.0001, respectively). For that reason, the HLA pattern of the patient served here as a biomarker and allowed stratification of patients who would respond to the treatment \[[@CIT0062]\].

Mackiewicz *et al*. presented the results of two phase II clinical studies (trials 3 and 5) conducted in almost 200 patients after resection of stage IIIB, C and IV melanoma \[[@CIT0063]\]. In both studies patients were vaccinated with only one in the class of allogeneic genetic vaccines AGI-101 composed of two irradiated melanoma cell lines modified to express Hyper-IL-6 -- a fusion protein composed of interleukin 6 (IL-6) and soluble IL-6 receptor. AGI-101 (5 × 10^7^ cells per dose) was administered 8 times at 2-week intervals (induction phase) and then monthly (maintenance phase). At disease progression the induction phase (+/-- surgery) was restarted, followed by a second maintenance phase. At progression 43 (trial 3) and 39 (trial 5) patients were re-induced +/-- surgery followed by a second maintenance phase; of those 11 and 16 patients respectively are alive following re-induction. Disease-free survival (DFS) probability at 5 years for trials 3 and 5 was 54.8% and 40.6% for stage IIIB, 25.0% and 24.0% for IIIC, and 8.5% and 17.7% for IV. The 5-year survival in trial 3 was 66.7%, 43.8% and 26.1% respectively in stage IIIB, IIIC and IV. In trial 5 the 5-year survival was as follows: 56.3%, 39.8% and 41.2% correspondingly in stage IIIB, IIIC and IV. The OS observed in trial 3 was 4.4 years and 3.1 years in trial 5. The vaccine was well tolerated as no vaccine-related toxicity of CTC \> 2 was detected \[[@CIT0063]\]. In our studies the median DFS of treated patients was at least 3 times longer than control patients in three large randomized trials \[[@CIT0064]--[@CIT0066]\]. In the EORTC 18891 study, the median DFS of patients in the control arm was 1.6 and 0.64 years for stage IIIB and IIIC, respectively, with 33% and 15.7% of patients surviving 4 years \[[@CIT0064]\]. In patients with stage IIIB, IIIC and IV, Eigentler *et al*. reported median DFS of 0.63 years and 15% of patients disease free at 5 years \[[@CIT0065]\]. Bystryn *et al*. reported for placebo patients the median DFS of 0.64 years with 23% of patients disease free at 2 years \[[@CIT0066]\]. Furthermore, in a recently presented meta-analysis including 33 trials evaluating survival in patients with resected and unresected stage IV melanoma, the 2-year OS rate observed in patients after surgical resection of metastases was only 27% \[[@CIT0067]\].

Broad research on DCs demonstrated that they are the most efficient APCs \[[@CIT0068], [@CIT0069]\]. DCs play a crucial role in inducing the immune response. They are the only representatives of APCs that are capable of inducing a primary response of virgin T lymphocytes. The use of DCs for antigen presentation offers an opportunity to trigger an immune response even to weakly immunogenic tumour antigens and break immune tolerance. A phase III study conducted in metastatic melanoma patients evaluated the efficacy of autologous DCs pulsed with peptides presented in the context of HLA class I and II. In the control arm patients were treated with DTIC. However, the study was terminated after preliminary analysis due to the lack of superiority of the vaccine over DTIC \[[@CIT0070]\]. Nevertheless, only 53 patients in the vaccine group and 55 in the control arm were participating in the trial and the vaccine was administered depending on the amount of DC (two up to five times; only 14 patients received more than 6 doses). However, subsequent analysis demonstrated that vaccinated patients with HLA-A2 +/HLA-B44 haplotype showed longer survival than those treated with DTIC \[[@CIT0071]\]. DC vaccine was also tested in patients with high-risk resected melanoma (stage III and IV). In one study arm 56 patients (stage III -- 46, IV -- 10) were treated with autologous monocyte-derived DC vaccine primed with autologous tumour lysate. In the control group 53 patients (stage III -- 47, IV -- 5) underwent observation. At a median follow-up of 22 months DFS was significantly longer in vaccinated patients (HR 0.45; 95% CI: 0.29--0.69; *p* \< 0.05), but there was no difference in OS between the study arms (HR 0.71; 95% CI: 0.40--1.25; *p* = 0.23). 60% of patients treated with the DC vaccine remained alive at the time of study analysis. The investigators observed a significant correlation between reduction of risk and vaccine-induced strong delayed type hypersensitivity reaction \[[@CIT0072]\].

Intensive research on melanoma vaccines is currently being carried out worldwide. However, no vaccine in the treatment of melanoma has been approved by regulatory authorities so far.

Future perspectives {#S0012}
===================

In recent years significant progress in the treatment of advanced melanoma has been seen. However, for further improvement identification of good response biomarkers is needed. Also we need to learn how to evaluate and identify responses that would eventually mean survival advantages. Likewise, management of drug resistance is a big challenge in melanoma treatment. Combination therapy including MEK and BRAF inhibitors in overcoming resistance to BRAF inhibitors in patients with BRAF mutated metastatic melanoma needs confirmation in upcoming phase 3 studies. Also development of successful BRAF inhibitor/immune therapy-based (anti-CTLA4 or anti-PD1 therapy) combinations offers the real possibility that very durable responses could be achieved. Likewise, strategies composed of immunomodulating agents and cancer vaccines may result in higher efficacy of the treatment with fewer adverse events related to drugs modulating the immune system.
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